Valence ロゴ
人気
ログイン

ウォッチリストに追加

Haemonetics Corporation

NYSE: HAE · リアルタイム株価 · USD
104.65
+14.38 (15.93%)
終値時点： Aug 18, 2026, 3:59 PM

Haemonetics Corporation (HAE) Stock Price, Analysis & Data

15.93%
買気配n/a
時価総額4.76B
売上高（TTM）1.35B
純利益（TTM）96.29M
ベータ0.52
EPS（TTM）2.4
PER（TTM）43.6
予想PER18.23
PBR（TTM）5.68
PSR（TTM）3.52
Earnings DateNov 5, 2026
売気配n/a
出来高2,304,602
平均出来高（20日）882,340
始値102.50
前日終値90.27
当日レンジ102.00 - 106.67
52週レンジ47.32 - 106.67
アナリストBuy
目標株価96 (-8.27%)
配当n/a
権利落ち日n/a

HAEについて

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma c...

[続きを読む]
業種 Medical Devices
セクター Healthcare
IPO日 May 10, 1991
従業員数 3,009
上場取引所 NYSE
ティッカー HAE
ウェブサイト https://www.haemonetics.com
企業情報の全文

業績

2026年のHaemoneticsの売上高は1.33Bで、前年の1.36Bから-1.97%の減少でした。 利益は97.31Mで、-41.97%の減少でした。

財務諸表

アナリスト予想

10件のアナリスト評価によると、HAE株の平均レーティングは「Buy」です。12か月後の目標株価は96で、直近株価から8.27%の下落余地となります。

株価予想

決算サプライズ

HaemoneticsはAug 6, 2026に四半期決算を発表しました：
  • 売上高は $339.38M で、予想を下回りました $0, うち 5.60% の前年比増加にあたります.
  • EPSは 1.14 で、予想を上回りました 0.06, うち 3.64% の前年比増加にあたります.

    • 次回決算発表

    Haemonetics Corporationの決算発表予定日は Nov 5, 2026, 寄り付き前の予定です。
    アナリストの売上高予想は ... アップグレード
    news image

    8時間前 · MT Newswires

    Sector Update: Healthcare Stocks Climb Late Afternoon

    Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State S

    news image

    1日前 · StockStory

    1 Unpopular Stock That Deserves a Second Chance and 2 We Avoid

    When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other busine...

    news image

    3日前 · Simply Wall St.

    Haemonetics (HAE) Stock Could Be 49% Below Fair Value On Raised Guidance

    Haemonetics stock has delivered a strong 69.0% return over the past year, yet the valuation signals are mixed, with an intrinsic value estimate based on a Discounted Cash Flow (DCF) model suggesting t...

    news image

    3日前 · Simply Wall St.

    Haemonetics (HAE) Earnings Beat Puts Fair Value Back In Focus

    Haemonetics (HAE) has drawn fresh attention after reporting first quarter fiscal 2027 results, with sales of US$339.38 million and net income of US$33.01 million, alongside a US$391.25 million shelf r...

    news image

    3日前 · StockStory

    5 Insightful Analyst Questions From Haemonetics’s Q2 Earnings Call

    Haemonetics delivered a Q2 performance that surpassed Wall Street’s revenue and adjusted earnings expectations, supported by consistent execution across its business lines. Management attributed the q...

    2ページ中1ページ